Gujarat Kidney & Super Speciality
GKSL NSE
Gujarat Kidney & Super Speciality
Healthcare ServicesNSE: GKSL BSE: 544666 Hospitals
Key Fundamentals
MicrocapHospitalsHealthcare ServicesMarket Cap
₹1,367 Cr
Volatility
High Risk
P/E Ratio
79.95
EBITDA
₹26.94 Cr
Return on Equity
35.02%
Debt to Equity
0.11
Book Value
₹32.03
52W High
₹180.9
52W Low
₹98.36
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is expected to give good quarter
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 172 days.
- Working capital days have increased from 55.7 days to 91.1 days
Growth Rate
Revenue Growth
103% lower than
3Y
Net Income Growth
68.84%
Cash Flow Change
—
ROE
121% higher than
3Y
ROCE
178%
EBITDA Margin (Avg.)
-21.38% higher than
3Y
Quarterly Results
| Particulars | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9.41 | 11.79 | 9.78 | 15.26 | 12.93 | 23.25 | 30.58 | 34.29 |
| Expenses | 4.55 | 7.19 | 7.17 | 6.64 | 7.81 | 16.35 | 24.28 | 25.92 |
| Operating Profit | 4.86 | 4.6 | 2.61 | 8.62 | 5.12 | 6.9 | 6.3 | 8.37 |
| OPM % | 51.65% | 39.02% | 26.69% | 56.49% | 39.6% | 29.68% | 20.6% | 24.41% |
| Other Income | 0.04 | 0.05 | 0.05 | 0.01 | 0.09 | 0.06 | 0.71 | 0.69 |
| Interest | 0.16 | 0.17 | 0.16 | 0.18 | 0.28 | 0.6 | 0.82 | 0.66 |
| Depreciation | 0.74 | 0.88 | 0.9 | 0.96 | 0.9 | 1.33 | 1.51 | 1.44 |
| PBT | 4 | 3.6 | 1.6 | 7.49 | 4.03 | 5.03 | 4.68 | 6.96 |
| Tax % | 26.25% | 29.72% | 16.88% | 27.77% | 28.54% | 26.44% | -2.99% | 23.56% |
| Net Profit | 2.96 | 2.53 | 1.34 | 5.4 | 2.88 | 3.7 | 4.82 | 5.32 |
| EPS in Rs | 18.39 | 15.53 | 0.23 | 0.85 | 0.47 | 0.37 | 0.64 | 0.66 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 0 | 5 | 40 | 82 | 101 |
| Expenses | 0 | 3 | 24 | 55 | 74 |
| Operating Profit | 0 | 2 | 17 | 27 | 27 |
| OPM % | — | 41% | 41% | 33% | 26% |
| Other Income | 0 | 1 | 0 | 1 | 2 |
| Interest | 0 | 0 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 3 | 5 | 5 |
| PBT | 0 | 2 | 13 | 21 | 21 |
| Tax % | 0% | 25% | 26% | 21% | — |
| Net Profit | 0 | 2 | 10 | 17 | 17 |
| EPS in Rs | -0.5 | 85.5 | 1.66 | 1.97 | 2.14 |
| Div. Payout % | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 0.2 | 0.2 | 11 | 16 |
| Reserves | 0 | 11 | 15 | 237 |
| Borrowings | 0 | 6 | 8 | 29 |
| Other Liabilities | 4 | 4 | 21 | 16 |
| Total Liabilities | 4 | 21 | 55 | 298 |
| Fixed Assets | 0 | 14 | 31 | 129 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 7 | 24 | 169 |
| Total Assets | 4 | 21 | 55 | 298 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 0 | 1 | 14 | -4 |
| Investing | 0 | 0 | -18 | -214 |
| Financing | 0 | 0 | 6 | 228 |
| Net Cash Flow | 0 | 1 | 2 | 11 |
| Free Cash Flow | 0 | 2 | -5 | -15 |
| CFO/OP | 0 | 70 | 99 | -14 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | — | 321 | 138 | 172 |
| Inventory Days | — | — | — | 82 |
| Days Payable | — | — | — | 339 |
| Cash Conversion Cycle | — | 321 | 138 | -84 |
| Working Capital Days | — | 100 | -24 | 91 |
| ROCE % | — | 19% | 52% | 14% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Gujarat Kidney & Super Speciality insights
29 extracted metrics + investor summaries across FY23–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Company filed initial large corporate disclosure; outstanding borrowing was Rs 1.23 crore and not a large corporate. 30 Apr - Company filed initial large corporate disclosure; outstanding borrowing was Rs 1.23 crore and not a large corporate.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Company filed initial large corporate disclosure; outstanding borrowing was Rs 1.23 crore and not a large corporate. 30 Apr - Company filed initial large corporate disclosure; outstanding borrowing was Rs 1.23 crore and not a large corporate.
3
Appointment of Company Secretary and Compliance Officer
27 Apr - Board approved new Company Secretary, 100% WOS incorporation, and noted shareholder approvals on April 27, 2026. 27 Apr - Board approved new Company Secretary, 100% WOS incorporation, and noted shareholder approvals on April 27, 2026.
4
Announcement under Regulation 30 (LODR)-Acquisition
27 Apr - Board approved new Company Secretary and WOS incorporation for healthcare expansion in Bharuch, effective 27 April 2026. 27 Apr - Board approved new Company Secretary and WOS incorporation for healthcare expansion in Bharuch, effective 27 April 2026.
5
Appointment of Company Secretary and Compliance Officer
6h - Board approved new Company Secretary, 100% WOS incorporation, and noted shareholder approvals on April 27, 2026. 6h - Board approved new Company Secretary, 100% WOS incorporation, and noted shareholder approvals on April 27, 2026.
Frequently Asked Questions about Gujarat Kidney & Super Speciality
What does Gujarat Kidney & Super Speciality Ltd do?
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
Where is Gujarat Kidney & Super Speciality Ltd (GKSL) listed?
Gujarat Kidney & Super Speciality Ltd trades as GKSL on the NSE and under code 544666 on the BSE.
Which sector does Gujarat Kidney & Super Speciality Ltd belong to?
Gujarat Kidney & Super Speciality Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the market capitalisation of Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd has a market capitalisation of ₹1,367 Cr, which places it in the Small Cap band.
What is the PE ratio of Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd trades at a PE ratio of 79.95, against a book value of ₹32.03 per share.
What is the 52-week high and low of Gujarat Kidney & Super Speciality Ltd?
Over the last 52 weeks Gujarat Kidney & Super Speciality Ltd has traded between ₹98.36 and ₹180.9.
What is the Return on Equity (ROE) of Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd reported a return on equity of 35.02%. Its debt-to-equity ratio is 0.11.
Company Information
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
CEO Mr. Pragnesh Yashwantsinh Bharpoda
Employees 338
Listed 2025-12-30
Face Value ₹ 2
Issued Size 7,88,43,250
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GKSL.md for Gujarat Kidney & Super Speciality Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.